NASDAQ:QNCX

Quince Therapeutics Stock News

Healthcare > Biotechnology

Buy QNCX

*Your capital is at risk

$23.39

+0.360 (+1.56%)

At Close: Jul 31, 2026

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

04:05pm, Monday, 11'th Aug 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

08:00am, Wednesday, 16'th Jul 2025

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

04:05pm, Thursday, 10'th Jul 2025

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

04:05pm, Wednesday, 25'th Jun 2025

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

04:05pm, Wednesday, 18'th Jun 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX) (“Quince” or the “Company”), a late-stage biotechnology company dedicated to unlocking

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

05:15pm, Thursday, 12'th Jun 2025

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

04:05pm, Tuesday, 03'rd Jun 2025

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

09:50am, Thursday, 15'th May 2025

Quince Therapeutics is advancing eDSP for Ataxia-Telangiectasia, leveraging strong prior data in the 6-9 age group and an innovative AIDE platform. Recent insider buying, new analyst coverage with hig